Meeting
2021 ASCO Annual Meeting
Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).
Authors
Miguel Martin
Hospital General Universitario Gregorio Marañón, Madrid, Spain
Miguel Martin , Roberto Hegg , Sung-Bae Kim , Michael Schenker , Daniela Grecea , José A. García-Sáenz , Konstantinos Papazisis , Quchang Ouyang , Aleksandra Lacko , Berna Oksuzoglu , James Andrew Reeves Jr., Meena Okera , Laura Testa , Chikako Shimizu , Ran Wei , Tammy D Forrester , Maria Munoz , Annamaria H. Zimmermann , Desiree Headley , Stephen R. D. Johnston
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT03155997
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 517)
DOI
10.1200/JCO.2021.39.15_suppl.517
Abstract #
517
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.
First Author: Marie N. Becker
Poster
2021 ASCO Annual Meeting
eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
First Author: Sara M. Tolaney
Poster
2023 ASCO Annual Meeting
Utility of Ki67 in guiding adjuvant abemaciclib therapy for patients with hormone receptor (HR)-positive, early breast cancer (EBC).
First Author: Rima Patel
Poster
2023 ASCO Annual Meeting
Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.
First Author: Sylvie Giacchetti